An observational study in Polycystic Ovarian Syndrome (PCOS), sponsored by Cumhuriyet University. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 43 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Cumhuriyet University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Polycystic Ovary Syndrome with a site in Turkey — 14 open to participants now, 15 under way, none of them phase 3. Polycystic Ovary Syndrome · Turkey.
Among the 72 studies in Polycystic Ovary Syndrome with a site in Turkey, this one is the 36th largest by enrollment of the 43 observational ones that give a count, is one of 10 that started in 2024, is one of 43 observational ones, and was the 68th registered.
959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →14 of the 72 studies in Polycystic Ovary Syndrome with a site in Turkey are open now. Recruiting first, the newest first:
Atlas University · Sites in Turkey
Ages 18–45 · Women only
Istanbul Health and Technology University · Sites in Turkey
Ages 18–40 · Women only · Healthy volunteers
Dicle University · Sites in Turkey
Ages 20–40 · Women only
Ege University · Sites in Turkey
Ages 18–40 · Women only
Marmara University · Sites in Turkey
Ages 18+ · Women only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 43 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 118 across 223 observational studies indexed under Polycystic Ovary Syndrome.
Median enrollment 54 across the 29 interventional studies, 90 across the 43 observational. Of the 50 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 72 has an industry lead sponsor. The 10 most frequent:
Cumhuriyet University is the lead sponsor of 135 studies on the registry; 26 are open to participants now.
Cumhuriyet University has 1 study filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Polycystic Ovary Syndrome with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07896642Istanbul Health and Technology UniversityBrown Adipose Tissue Modulation in Polycystic Ovary Syndrome Using Infrared Thermography | 2026-12 |
| NCT07509762Biruni UniversityExercise Programs in Women With PCOS | 2027-01-15 |
| NCT07871851Inonu UniversityInvestigation of the Effectiveness of Spinal Stabilization Exercises Added to Aerobic Exercise in Women With Polycystic Ovary Syndrome | 2027-01-20 |
| NCT07342946Atlas UniversityThe Effects of the Mediterranean Diet and Synbiotics in Polycystic Ovary Syndrome | 2027-04-01 |
| NCT07731373Kayseri City HospitalBiomarker Panel for PCOS-Associated Liver Steatosis in Adolescent Girls (COMPASS-pedPCOS) | 2027-04-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 72 studies in Polycystic Ovary Syndrome with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective observational case-control study evaluated serum BRCC36 and telomerase (TE) levels in women with polycystic ovary syndrome (PCOS) and healthy controls. Women aged 18-43 years were included. The study comprised 30 women diagnosed with PCOS according to ESHRE/ASRM criteria and 30 healthy women with regular menstrual cycles. A single 5-mL venous blood sample was collected from each participant. Serum was separated by centrifugation and stored at -80°C until analysis. Serum BRCC36 and telomerase levels were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits. The study evaluated differences in these biomarkers between women with PCOS and healthy controls and their relationships with clinical and biochemical characteristics.
This prospective observational case-control study included women aged 18-43 years with polycystic ovary syndrome (PCOS) and healthy controls. PCOS was diagnosed according to ESHRE/ASRM criteria based on the presence of at least two of the following features: oligo- and/or anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasonography.
Participants underwent clinical and anthropometric evaluation, including body mass index and modified Ferriman-Gallwey scoring. Available biochemical and hormonal parameters obtained during routine clinical evaluation were also recorded.
For the study-specific biomarker analyses, a single 5-mL venous blood sample was collected from each participant into a serum separator tube. Samples were centrifuged at 3000 rpm for 10 minutes, and the separated sera were stored at -80°C until analysis. Serum BRCC36, a deubiquitinating enzyme-related biomarker, and telomerase (TE) levels were measured using commercially available human ELISA kits.
The primary objective was to compare serum BRCC36 and telomerase levels between women with PCOS and healthy controls. Associations between these biomarkers and clinical and biochemical characteristics were also evaluated.
Women aged 18-43 years attending Sivas Cumhuriyet University Faculty of Medicine Hospital were included. The study population consisted of 30 women diagnosed with PCOS according to ESHRE/ASRM criteria and 30 healthy women with regular menstrual cycles who served as controls. All participants were non-obese (BMI \<30 kg/m²) and provided written informed consent.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women aged 18-43 years diagnosed with polycystic ovary syndrome according to ESHRE/ASRM criteria (n=30).
Healthy women aged 18-43 years with regular menstrual cycles and without clinical or ultrasonographic features of PCOS (n=30).
Serum BRCC36 Level
Serum BRCC36 levels measured using a commercially available human ELISA kit and compared between the PCOS and healthy control groups.
Time frame: At study enrollment (single blood collection)
Serum Telomerase Level
Serum telomerase (TE) levels measured using a commercially available human ELISA kit and compared between the PCOS and healthy control groups.
Time frame: At study enrollment (single blood collection)
Plan to share: No — maybe after de article submission i will plan to share.
No publications or documents are linked to this record.
Ran from Feb 2024 to primary completion in Feb 2025, 12 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.